Sonnet BioTherapeutic News

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20

BenzingaDec 20 06:29 ET · Ratings

Sonnet BioTherapeutics Analyst Ratings

BenzingaDec 20 06:23 ET · Ratings

Sonnet BioTherapeutic | 10-K: FY2024 Annual Report

SECDec 17 09:03 ET · Announcements

Express News | Sonnet BioTherapeutics FY 2024 GAAP EPS $(11.35)

BenzingaDec 17 08:53 ET

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

GlobeNewswireDec 17 08:50 ET

Express News | Sonnet Biotherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

ReutersDec 17 08:50 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaDec 9 16:05 ET

Express News | Sonnet BioTherapeutics Announces $3.9M Registered Direct Offering And Concurrent Private Placement, Selling 1.76M Shares And Warrants Priced At-The-Market Under Nasdaq Rules With $2.23 Combined Price And $2.10 Warrant Exercise Price

BenzingaDec 9 15:43 ET

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeuticDec 9 15:42 ET

Sector Update: Health Care Stocks Edge Higher Monday Afternoon

MT NewswiresDec 9 13:48 ET

Sector Update: Health Care

MT NewswiresDec 9 13:30 ET

Sonnet BioTherapeutics Shares Are Trading Higher After the Company Announced the Highest Dose of Its Phase 1 SB101 Trial Results for SON-1010 Have Been Formally Evaluated by the Safety Review Committee, With the Maximum Tolerated Dose Set at 1200ng/kg.

BenzingaDec 9 10:57 ET

Trending Stocks Today | LeddarTech Surges 422.24%

Moomoo NewsDec 9 09:50 ET

Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization

MT NewswiresDec 9 09:28 ET

Express News | Sonnet Biotherapeutics Holdings Inc - Update on Safety at Mtd Expected in Q1 2025

ReutersDec 9 08:45 ET

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeuticDec 9 08:45 ET

Express News | Sonnet Biotherapeutics Announces Topline Safety Data Following Successful Completion of Son-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

ReutersDec 9 08:45 ET

Express News | Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039

BenzingaDec 4 09:21 ET

Sonnet BioTherapeutics Releases Virtual Investor '"What This Means" Segment

GlobeNewswireNov 12 09:15 ET

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswireNov 6 13:20 ET